SCHEMBL374772

SCHEMBL374772

O=C(Cl)c1ccccc1Nc1c(Cl)cccc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 6/20 0.55
CXCL8 P10145 3/20 0.55
PTGS1 P23219 3/20 0.55
TTR P02766 3/20 0.55
MT-CO2 P00403 2/20 0.55
ADRA1A P35348 2/20 0.55
AKR1B10 O60218 2/20 0.55
ABCB11 O95342 2/20 0.55
UGT1A9 O60656 1/20 0.55
TRPA1 O75762 1/20 0.55
ALB P02768 1/20 0.55
UGT1A6 P19224 1/20 0.55
UGT1A1 P22309 1/20 0.55
CXCR1 P25024 1/20 0.55
AGTR2 P50052 1/20 0.55
NR1I3 Q14994 1/20 0.55
SLC22A6 Q4U2R8 1/20 0.55
NR1H4 Q96RI1 1/20 0.55
UGT1A7 Q9HAW7 1/20 0.55
UGT1A10 Q9HAW8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL374641 0.86 FTO (0.71) PTGS2PTGS1TTRMT-CO2ADRA1A
SCHEMBL11407549 0.84 CXCL8 (0.55) PTGS2CXCL8PTGS1TTRMT-CO2
SCHEMBL9735209 0.83 FTO (0.56) PTGS2CXCL8PTGS1TTRMT-CO2
SCHEMBL11518282 0.83 PTGS2 (0.56) PTGS2CXCL8PTGS1TTRMT-CO2
SCHEMBL20587939 0.82 FABP4 (0.53) PTGS2PTGS1TTRMT-CO2ADRA1A
SCHEMBL11451926 0.81 PTGS2 (0.72) PTGS2CXCL8PTGS1TTRMT-CO2
SCHEMBL11013086 0.81 PTGS2 (0.79) PTGS2CXCL8PTGS1TTRMT-CO2
Acetamide SCHEMBL27431923 0.80 CXCL8 (0.57) PTGS2CXCL8PTGS1TTRMT-CO2
SCHEMBL11517374 0.79 CLCN2 (0.53) PTGS2CXCL8PTGS1TTRMT-CO2
SCHEMBL2515246 0.79 CXCL8 (0.50) PTGS2CXCL8PTGS1TTRMT-CO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111116391-A Preparation method of sodium 2- [ (2, 6-dichlorophenyl) amino ] phenylacetate 浙江工业大学 2020-05-08 CN disclosed
US-8575217-B2 Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders GENMEDICA THERAPEUTICS SL (ES) 2013-11-05 US disclosed
US-8575217-B2 Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders GENMEDICA THERAPEUTICS SL (ES) 2013-11-05 US disclosed
US-8575217-B2 Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders GENMEDICA THERAPEUTICS SL (ES) 2013-11-05 US disclosed
US-20130281520-A1 Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders GENMEDICA THERAPEUTICS SL (ES) 2013-10-24 US disclosed
US-20130281520-A1 Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders GENMEDICA THERAPEUTICS SL (ES) 2013-10-24 US disclosed
EP-2408443-A1 ANTI-INFLAMMATORY AND ANTIOXIDANT CONJUGATES USEFUL FOR TREATING METABOLIC DISORDERS Genmedica Therapeutics SL (ES) 2012-01-25 EP disclosed
WO-2010106082-A1 ANTI-INFLAMMATORY AND ANTIOXIDANT CONJUGATES USEFUL FOR TREATING METABOLIC DISORDERS GENMEDICA THERAPEUTICS SL (ES) 2010-09-23 WO disclosed
US-20100234452-A1 Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders GENMEDICA THERAPEUTICS SL (ES) 2010-09-16 US disclosed
US-20100234452-A1 Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders GENMEDICA THERAPEUTICS SL (ES) 2010-09-16 US disclosed
US-20100234452-A1 Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders GENMEDICA THERAPEUTICS SL (ES) 2010-09-16 US disclosed
US-4189595-A [N-benzyl-o-(2,6-dichloroanilino)phenyl]acetic acid derivatives NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1980-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281520-A1 Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders HSD17B14, SORD, GPX4 PTGS2 169/4885CXCL8 1815/4885PTGS1 93/4885
US-20100234452-A1 Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders HSD17B14, SORD, GPX4 PTGS2 169/4885CXCL8 1815/4885PTGS1 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.